Model parameters for cementless prostheses and estimated values of QALYs, NMB and tender score (reference population: men aged 70 years)
| Corail/ Pinnacle | Accolade/ Trident | Taperloc/ Exceed | |
| Utility at 6 months after surgery* | 0.82 | 0.82 | 0.82 |
| Annual revision rate† | 0.43 | 0.54 | 0.44 |
| QALYs per patient‡ | 8.2092 | 8.2091 | 8.2092 |
| Cost per patient (£)§ | 8306 | 8088 | 7829 |
| NMB per patient (£) | 1 55 879 | 1 56 095 | 1 56 356 |
| Tender score | 0 | 45.28 | 100 |
*The values of utility were recalculated from those of the study by Pennington et al 9 as the average of the three brand-related means, weighted for their respective number of patients; see also Hunt et al 15 for further explanations.
†Calculated from the rate at 10 years reported by Pennington et al 9 divided by 10.
‡QALYs were re-estimated using the Markov model described in Messori.11
§The costs per patient are those published by Pennington et al 9 and include the cost of the device and all treatment-related costs.
Other parameters of the model (common to the nine devices) were time horizon= 20 years; annual discount rate=3.5%; death rate at surgery=0.29% (according to Hunt et al 12).
NMB, net monetary benefit; QALY, quality-adjusted life year.